TACSTD1 MaxPab Mouse Polyclonal Antibody
- Known as:
- TACSTD1 MaxPab Mouse Polyclonal Antibody
- Catalog number:
- BIN-004072-B01
- Product Quantity:
- 0.05ml
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- TACSTD1 MaxPab Mouse Polyclonal Antibody
Related genes to: TACSTD1 MaxPab Mouse Polyclonal Antibody
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: TACSTD1 MaxPab Mouse Polyclonal Antibody
Related articles to: TACSTD1 MaxPab Mouse Polyclonal Antibody
- Direct lineage reprogramming offers a highly promising non-genetic pathway for generating functional somatic cells. In this study, a single small molecule inhibitor of the BMP pathway, LDN193189, was able to directly reprogram goat ear fibroblasts into Chemically induced Mammary Epithelial Cells (CiMECs) in vitro within 8 days. The generated CiMECs displayed typical epithelial morphology, expressed key mammary epithelial markers (including KRT8/14/18/19, CD49f, and EpCAM), and exhibited potent secretory functions: they could form lipid droplets and produce milk proteins such as lactoferrin (LTF) and αS2-casein (αS2-CSN). Single-cell RNA sequencing revealed a stepwise reprogramming trajectory: starting from mesenchymal-epithelial transition (MET), through ectoderm-like and epidermal-like intermediate states to differentiate into basal and lumenal mammary epithelial cells, which involves multiple signaling pathways related to mammary gland development, such as TGF-β, MAPK, and PI3K-Akt. Functionally, CiMECs could self-assemble in vitro to form three-dimensional mammary-like organs. In addition, in vivo transplantation experiments in nude mice showed that these CiMECs survived and contributed to ductal- and basal-like tissue structures, confirming their in vivo regenerative potential. In conclusion, this study establishes a simple somatic cell-based platform with a well-defined chemical composition to efficiently generate functional mammary epithelial cells, providing an important model for mammary developmental studies and opening up promising strategies for regenerative medicine and bioreactor engineering applications. - Source: PubMed
Liu QuanhuiZhang DandanWang GuodongLei ZhigangDeng ShanXiao LiangguiQin MengqinHuang Ben - Despite extensive validation of lysyl oxidase-like 2 (LOXL2) as a therapeutic target in metastatic cancer, there have been few therapeutic applications of corresponding inhibitors until now. Herein, we reported the design, synthesis, and biological evaluation of two series of 4-(aminomethyl)-2-(phenylamino)pyridine derivatives (7a-7u and 10a-10u) as novel LOXL2 inhibitors for metastatic melanoma intervention. Structure-based optimization of 2-substituted pyridine-4-ylmethanamine scaffold led to the identification of 10q, exhibiting notable LOXL2 inhibitory activity with IC value of 79.38 nM, superior to the lead compound. In invasive melanoma cells, 10q dose-dependently inhibited proliferation, invasion, migration, and cell-matrix adhesion as well as attenuating focal adhesions (FAs) and stress fibers (SFs) formation. Further mechanism studies revealed that 10q treatment disrupted LOXL2-mediated signaling cascades, as evidenced by decreased phosphorylation of FAK, PI3K, AKT, and mTOR, concomitant with downregulation of Snail 1 and upregulation of the epithelial marker E-cadherin. Collectively, these results indicated that 10q is a novel LOXL2 inhibitor with potent anti-metastasis activity, highlighting its potential as a promising candidate for the intervention of metastatic melanoma. - Source: PubMed
Publication date: 2026/05/30
Yu GengQiu YaorenXie JieLin JieDong XuGu XinyuJiang DejunTan GuishanCao DongshengDeng YouchaoKang Fenghua - The cell surface protein of EpCAM (Epithelial Cell Adhesion Molecule), also known as CD326, is generally expressed in normal epithelia; whereas, its upregulation has been reported in certain tissue stem cells, precursors, and a number of epithelium-derived tumors. EpCAM was initially introduced as a transmembrane glycoprotein modulating cell-cell adhesion and facilitating epithelial-specific intercellular cell adhesion. However, its recognized functions have expanded to include diverse roles in fundamental cellular processes, such as the regulation of proliferation, differentiation, cell migration, and cell signaling. The aim of the current review is to unravel the mechanisms by which EpCAM controls the initiation of cancer through interactions and the formation of a complex with Wnt pathway molecules; also, to summarize and discuss the original data obtained from international research laboratories on the properties of EpCAM, including its expression in human CSCs (Cancer Stem Cells) and CTCs (Circulating Tumor Cells). Questions such as how this property led to this molecule being considered as a modulator of epithelial plasticity or phenotypic flexibility rather than a true structural adhesion molecule that mdiates mechanical cell-cell adhesion, are also addressed. This review provides the significance of EpCAM-based identification in liquid biopsy and describes the main complications and challenges in its clinical applications for targeted therapeutic approaches. We also discuss new insights on EpCAM-targeted therapeutic approaches, including monoclonal antibodies, CAR-T cells, and bispecific antibodies. In conclusion, we discuss future research directions in which EpCAM targeting could contribute to further progress in cancer diagnosis, prognosis, and treatment. - Source: PubMed
Publication date: 2026/05/25
Ghari MehrzadGhaemimanesh Fatemeh - Longitudinal monitoring of tumor progression and metastasis provides significant benefits to improve the treatment outcome of breast cancer. Matrix metalloproteinase 14 (MMP14) on extracellular vesicles (EVs) is highly relevant to tumor invasiveness, yet the sensitivity and specificity of detection are hindered by tremendous amounts of normal EVs amidst complex blood samples. Here we developed an ultrafast one-step dual-target orthogonal barcoding-based microscale thermophoretic extracellular vesicle (DOT-EV) assay to evaluate MMP14 levels on tumor-derived EVs (T-EVs). Leveraging the orthogonal barcoding of two allosteric aptamer probes targeting MMP14 and EpCAM, our assay specifically recognizes signals from MMP14 of tumor EVs and enhances the accuracy of clinical diagnosis. The microscale thermophoresis induces convection flow and accelerates DNA assembly on EVs, enabling ultrafast one-step detection of T-EV MMP14 within just 20 s, consuming 10 μL plasma samples. The T-EV MMP14 profiling on metastatic mouse models and patient samples of breast cancer demonstrated that the DOT-EV assay can monitor different development stages of the tumor and predict metastatic potential. Notably, triple-negative breast cancer was successfully differentiated from other subtypes. The DOT-EV assay offers a pioneering tool for noninvasive and precise diagnosis, progression monitoring, and metastasis prediction of cancer, showing great promise in advancing the clinical implementation of precision medicine. - Source: PubMed
Publication date: 2026/06/03
Chen AipengWang RuokeZou YanDing YueTian RuitingWang YuqingLan FangzhouWu QiaoyiZhang PengFang XiaoniYang Chaoyong - Germline testing is underutilized and varies by cancer diagnosis. We hypothesized that patient and clinician involvement in cascade testing of relatives varies by the cancer susceptibility (breast gastrointestinal [GI]) of the affected gene. - Source: PubMed
Publication date: 2026/06/03
Kurian Allison WAbrahamse PaulFurgal AllisonVeenstra Christine MCourser Rebecca RHofer Timothy PHodan RachelCaswell-Jin Jennifer LGomez Scarlett LWard Kevin CHamilton Ann SLiu LihuaAn Lawrence CKatz Steven J